Synlogic, Ginkgo expand microbial discovery pact, throwing $80M investment into the mix
For Ginkgo Bioworks, teaming up with Synlogic on a pilot discovery project late 2017 marked its foray into harnessing the therapeutic ability of its cell programming platform. Having since leaped into a new antibiotics effort with Roche, Ginkgo is anting up $80 million to go deeper with Synlogic.
The two companies, both based in the Cambridge/Boston hub, are unveiling a new collaboration in which Ginkgo will help optimize the microbial strains that Synlogic — a pioneer in reengineering non-pathogenic bacteria into medicines — has identified as viable drug candidates.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters